explore -WSS

explore

author：focus 2025-09-27 23:01:36 - browse：9497

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Eli Lilly to acquire Versanis in heated race for weight loss drugs

leisure time

WSS

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Care demand spikes challenge UnitedHealth’s provider arm

Startup Neumora takes a novel depression drug to Phase 3

Care demand spikes challenge UnitedHealth’s provider arm

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

knowledge

explore

leisure time

Cancer drug shortages should be causing more outrage

Congress likely to miss an opportunity to fix drug shortages issue

Virginia high school admissions case could be legal follow

Biden tests positive for Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Federal judge rules Oregon’s tough new gun law is constitutional

Wildfire smoke exposes gaps in outdoor worker protections

Group opposing PBM reform sets lobbying record

At least 13 dead in Texas as scorching temps continue

Mike Pence clashes with Tucker Carlson in Iowa

entertainment

Blood tests recalled over risk of missed heart attack diagnosis

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Key House panel plots a new health care package

A public scorecard can help hold safety

FDA approves RSV monoclonal antibody for infants, toddlers

Eli Lilly to acquire Versanis in heated race for weight loss drugs

focus

knowledge

leisure time

entertainment